Halozyme Therapeutics Profit Margin

As of the most recent data (June 2026), HALO shows a profit margin of 24.86%. That compares with 47.28% in the prior-year period — down 47.4% year over year. That is above the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HALO's profit margin is now 24.86% (was 47.28%) — a 47.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Halozyme Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. Halozyme Therapeutics is at 24.86%, which is higher that average. That is roughly 73.3% above the sector mean. Use the comparison chart on this page to see how HALO stacks up against individual peers as well.

That compares with 47.28% in the prior-year period — down 47.4% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Halozyme Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Halozyme Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 24.86%) with ownership activity and broader fundamentals.